Skip to main content
RT @Lupusreference: 🆒 Couldn't attend my #EULAR2022 talk about the role of #twitter in #Rheumatology?
Check the 2 sli

Laurent ARNAUD Lupusreference

4 weeks 1 day ago
🆒 Couldn't attend my #EULAR2022 talk about the role of #twitter in #Rheumatology? Check the 2 slides below summarizing the role of #socialmedia for the dissemination of medical information. #TwitterRheum ⬇️ BEFORE vs AFTER Twitter ⬇️ https://t.co/ZzVdoWYEMr
RT @DrAiLynTan: EULAR recommendations for management of #RheumatoidArthritis

6️⃣Glucocorticoids should be tapered &

Dr Ai Lyn Tan DrAiLynTan

4 weeks 1 day ago
EULAR recommendations for management of #RheumatoidArthritis 6️⃣Glucocorticoids should be tapered & discontinued as soon as clinically feasible 8️⃣JAKi can be used but consider risk factors via Prof Smolen #EULAR2022 https://t.co/7cocPSpgkH
RT @Janetbirdope: #good news and bad news. Avacopan works v well for steroid sparing in #GPA. It’s an oral C5a recepto

Janet Pope Janetbirdope

4 weeks 1 day ago
#good news and bad news. Avacopan works v well for steroid sparing in #GPA. It’s an oral C5a receptor blocker - maintains more remission and less relapses and less total prednisone OP0180 @eular_org #EULAR2022 @RheumNow Bad news $$💰 will limit access.
RT @Janetbirdope: #ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with

Janet Pope Janetbirdope

4 weeks 1 day ago
#ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with past MACE events. Some CV risks have different risks ex HTN May have less risk vs high cholesterol @RheumNow @eular_org #EULAR2022 POS0237 https://t.co/kTn4rxMlej
Watch: #EULAR2022 - Day 4 Faculty Panel Recap

Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0

Dr. John Cush RheumNow

4 weeks 1 day ago
Watch: #EULAR2022 - Day 4 Faculty Panel Recap Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.https://t.co/B7AYkTnAe0 https://t.co/NF3f6AFv6K
Update on Axial SpA at #EULAR2022

This year at EULAR 2022, there were important and interesting topics in Axial Spondy

Dr. John Cush RheumNow

4 weeks 1 day ago
Update on Axial SpA at #EULAR2022 This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). Dr Antoni Chan shares his picks of abstracts from the conference.https://t.co/AhUC7ORrZi https://t.co/1olLoNS5Ey
Spondyloarthritis and COVID-19

With the availability of vaccines and new therapeutics, many of our patients are fully v

Dr. John Cush RheumNow

4 weeks 1 day ago
Spondyloarthritis and COVID-19 With the availability of vaccines and new therapeutics, many of our patients are fully vaccinated. We know this can limit their chances of severe COVID all while allowing their rheumatic disease to be treated. #EULAR2022 https://t.co/PmQNKYg1Ao https://t.co/N4DJVYJqrL
WATCH: Not Your Kind of RA

Dr. David Liew discusses abstract OP0035 presented at #EULAR2022

Background: It has been su

Dr. John Cush RheumNow

1 month ago
WATCH: Not Your Kind of RA Dr. David Liew discusses abstract OP0035 presented at #EULAR2022 Background: It has been suggested that rheumatoid arthritis (RA) starts at a younger age in cities with a lower latitude (closer to both sides of the equator). https://t.co/0l8b95emkn https://t.co/2leBR1nOBJ
exhibitor.floor.ACR
Bags are packed, ready to go, but wait there’s more abstracts to show. The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased.  Here are my favorite late-breakers from Day 4.
Axial Spondyloarthritis
This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.
cancer search news magnify
For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic medications and malignancy risk has been largely reassuring, clinical trials have often excluded patients with history of cancer.
×